**Amendments to the Specification**

Please replace the paragraph beginning at page 4, line 10 with the following replacement paragraph:

The antibiotics used in the compositions and methods of the present invention have the following formula:

(I)



wherein:

A is CH, CF, CCl, C–$OCH_3$, or N;

$X^1$ is H, halogen, $NH_2$, or $CH_3$;

$R^1$ is $C_1$ to $C_3$ alkyl, $FCH_2CH_2$, cyclopropyl or phenyl, optionally mono-, di- or tri-substituted by halogen, or A and $R^1$ together can form a bridge of formula C–O–$CH_2$–$CH(CH_3)$;

$R^2$ is H, $C_1$ to $C_3$ alkyl (optionally substituted by OH, halogen or $NH_2$), or 5-methyl-2-

oxo-1,3-dioxol-4-yl-methyl; and

B is a selected from the group consisting of:







wherein:

Y is O or $CH_2$;

$R^3$ is $C_2$-$C_5$ alkoxyl, $CH_2$-CO-$C_6H_5$, $CH_2CH_2CO_2R'$, $R'O_2C$-CH=C-$CO_2R'$, CH=CH-$CO_2R'$ or $CH_2CH_2$-CN,

wherein:

R' is H or $C_1$ to $C_3$ alkyl;

R4 is H, $C_1$ to $C_3$ alkyl, $C_2$-$C_5$ alkoxyl, $CH_2$-CO-$C_6H_5$, $CH_2CH_2CO_2R'$, $R'O_2C$-CH=C-$CO_2R'$, CH=CH-$CO_2R'$, CH=CH-$CO_2R'$, $CH_2CH_2$-CN r 5-methyl-2-oxo-1,3-dioxol-4-yl-methyl,

wherein:

R' is H or $C_1$ to $C_3$ alkyl; and their pharmaceutically useful hydrates and salts.

Please replace the paragraph bridging pages 5 and 6 (and amended by paper filed March 9, 2006) with the following replacement paragraph:

The compound Moxifloxacin is most preferred. Moxifloxacin has the following structure:







---

Further details regarding the structure, preparation, and physical properties of Moxifloxacin and other compounds of formula (I) are provided in United States Patent No. 5,607,942.